D842V

One Perspective on the BLU-285 Trial (avapritinib/Ayvakit)

LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.

By |2020-03-09T10:18:42-04:00February 28th, 2020|D842V, News, Newsletter|

NCI Mentions LRG as Component in Development of Ayvakit

In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.

By |2020-02-07T14:23:48-05:00February 7th, 2020|D842V, Drug Treatment, News, Patient Registry|

Blueprint Medicines Presents Preclinical Data on BLU-285

Blueprint Medicines presented new preclinical data on its drug candidate, BLU-285, and its potential value in  treatment-resistant GIST and on novel cancer drug targets at the AACR (American Association for Cancer Research) Annual Meeting [...]

By |2019-04-08T10:13:47-04:00April 24th, 2015|D842V, News, Research|
Go to Top